Coloplast A/s Class B · OMXCOP:COLO_B
Coloplast A/s Class B — Non-Deal Roadshow (August 2024)
101 slides from Coloplast A/s Class B's roadshow presentation, August 2024
Slide 1: Roadshow presentation 9M 2023/24
Roadshow presentation 9M 2023/24 Making life easier Strive25: Sustainable Growth Leadership Theresa Continence Care user Ostomy Care | Continence Care | Advanced Wound Care | Interventional Urology | Voice and Respiratory Care
Slide 2: Forward-looking statements
Forward-looking statements The forward-looking statements contained in this presentation, including forecasts of sales and earnings performance, are not guarantees of future results and are subject to risks, uncertainties and assumptions that are difficult to predict. The forward-looking statements
Slide 3: Solid Q3 with 8% organic growth and 27% EBIT margin
Solid Q3 with 8% organic growth and 27% EBIT margin. Unchanged FY 2023/24 guidance of ~8% organic growth and 27-28% EBIT margin1. Revenue growth Q3 2023/24 highlights Reported revenue (mDKK) Organic growth • Organic growth of 8% and reported growth in DKK of 13%. Acquired growth from the Kerecis acq
Slide 4: Q3 organic growth of 8%, driven by Chronic Care and double-digit growth in Voice & Respiratory Care
Q3 organic growth of 8%, driven by Chronic Care and double-digit growth in Voice & Respiratory Care and Advanced Wound Care Q3 2023/24 revenue by business area Q3 2023/24 revenue by geography Business Reported revenue Organic growth Share of organic Geographic Reported revenue Organic growth Share o
Slide 5: Ostomy Care organic growth of 8% in Q3
Ostomy Care organic growth of 8% in Q3 with broad-based growth in Emerging Markets and Europe and improvement in growth in the US Ostomy Care performance Q3 2023/24 highlights • All regions contributed to growth in Q3: 9 • Growth in Emerging markets was broad-based across regions; China 8 8 8 delive
Slide 6: Solid Q3 in Continence Care with 8% organic growth
Solid Q3 in Continence Care with 8% organic growth, driven by Intermittent Catheters with strong contribution from Luja Continence Care performance Q3 2023/24 highlights • All regions contributed to growth in Q3: • Growth in Europe was driven by France and the UK. 9 9 • Broad-based growth in Emergin
Slide 7: Voice & Respiratory Care organic growth of 11% in Q3
Voice & Respiratory Care organic growth of 11% in Q3, driven by continued good momentum in both Laryngectomy and Tracheostomy Voice & Respiratory Care performance Q3 2023/24 highlights • Growth in the quarter was driven by continued good momentum in both Laryngectomy and Tracheostomy: • Laryngectomy
Slide 8: Advanced Wound Dressings grew 13% in Q3
Advanced Wound Dressings grew 13% in Q3 from a lower baseline. Kerecis continued the momentum with double-digit growth Advanced Wound Care performance Q3 2023/24 highlights 51 • Broad-based growth across regions in Advanced Wound Dressings, against a lower baseline last year: 40 36 • Europe was the
Slide 9: Interventional Urology grew 2% in Q3
Interventional Urology grew 2% in Q3, with solid momentum in Men’s Health, partly offset by Women’s Health and Bladder Health & Surgery Interventional Urology performance Q3 2023/24 highlights • Growth was driven by continued good momentum in the Men’s Health business in the US, driven by the Titan®
Slide 10: Q3 reported revenue grew 13%
Q3 reported revenue grew 13% with ~4%-points contribution from the Kerecis acquisition and ~1%-point positive impact from currencies Q3 2023/24 Revenue development (mDKK) Q3 2023/24 highlights • Reported revenue increased by DKK 777 million or 13% vs. last year. +777m DKK • Organic growth was 8% or
Slide 11: Reported EBIT margin of 27% in Q3
Reported EBIT margin of 27%1 in Q3, negatively impacted by ~100 basis points dilution from Kerecis, as expected, and currency headwind Q3 2023/24 EBIT margin development before special items (%) Q3 2023/24 highlights • Gross margin was 68%, against 66% in Q3 last year • Positive impact from: decreas
Slide 12: Adj. FCF of DKK 2,314 million in 9M
Adj. FCF of DKK 2,314 million in 9M. Operating cash flow impacted by the extraordinary tax payment related to the Atos Medical IP transfer FCF development1 9M 2023/24 highlights • Free cash flow for 9M 2023/24 was an outflow of DKK 186 million vs an 98 inflow of DKK 1,690 million last year, impacted
Slide 13: FY 2023/24 guidance unchanged
FY 2023/24 guidance unchanged with organic growth of ~8% and reported EBIT margin of 27-28%1 GUIDANCE 2023/24 GUIDANCE (DKK)* KEY ASSUMPTIONS • Solid momentum in Europe and Emerging Markets ex. China, in line with Strive25 ambitions • China Ostomy Care – improvement in growth, but below double-digit
Slide 14: FY 2023/24 margin and growth assumptions
FY 2023/24: continued good growth momentum; easing of inflationary headwinds and 1%-p EBIT margin dilution from Kerecis Revenue growth assumptions Key impacts on gross- and EBIT margin development in 2023/24 ILLUSTRATIVE FY 2023/24 organic growth expected around 8% ~68% in constant currencies ~67% ~
Slide 15: Making it easier to be yourself
Making it easier to be yourself Leading intimate healthcare Introduction to Coloplast Jurgen | OC user
Slide 16: Coloplast has five business areas all with global sales presence
Coloplast has five business areas all with global sales presence Group revenue 2022/23 by segment1 Group revenue 2022/23 by geography 1 Continence Care 1 32% European Ostomy Care markets 37% 57% Other developed markets DKK DKK 26% 24.5bn 4 24.5bn Interventional Urology 11% 1 Emerging Voice & 5 marke
Slide 17: Coloplast specializes in intimate healthcare needs
Coloplast specializes in intimate healthcare needs Who are our typical users How do we help them? Our brands Ostomy Care People who have had a part of their Adhesive ostomy bags SenSura® Mio digestive or urinary system redirected to an Supporting products Brava® opening in the abdominal wall Contine
Slide 18: The Chronic Care model secures a predictable revenue stream
The Chronic Care model secures a predictable revenue stream and stable revenue growth The chronic care user flow Chronic Care condition New user Installed base of users Stable flow of loyal users Solid reimbursement Coloplast group revenues Revenue (DKK bn) Organic growth (%) 10 9 8 8 8 8 8 7 6 7 6
Slide 19: Intimate healthcare is characterized by stable industry trends
Intimate healthcare is characterized by stable industry trends 01. 01. Demographics Surgical and medical trends Growing elderly population Earlier detection and cure, increases customer base for eventually reduces addressable Coloplast products market for Coloplast treatment Limiters Drivers product
Slide 20: Strong market positions in Europe and potential outside Europe
Coloplast has strong market positions in Europe and great commercial potential outside Europe Europe Other developed Emerging Ostomy Continence Voice & Respiratory Interventional Advanced 1 1 1 4 5 1 Global market position Care Care Care (Laryngectomy) Urology Wound Care Addressable market 41-44bn 2
Slide 21: We are building the consumer healthcare company of the future
We are building the consumer healthcare company of the future Macro Trends Impact Commercial model Ageing population Healthcare consumerism Digital transformation Price pressure Channel consolidation 21
Slide 22: Our Strive25 strategy supports long-term value creation
Our Strive25 strategy supports continued long- term value creation through revenue and earnings growth Long-term financial guidance 8-10% more than 30% organic growth EBIT margin p.a.1 beyond 2024/252 1 Raised to 8-10%, from previously 7-9%, on July 7 as a result of the acquisition of Kerecis, expec
Slide 23: Organic growth acceleration in the outer part of Strive25
Organic growth acceleration in the outer part of the Strive25 period and beyond through a balanced mix of organic and inorganic initiatives Illustrative, key moving parts 8-10% ~8% Strive25 Strive25 +1%-point ambition: ambition: accretion from Double-digit Launch of the FY 2024/25 organic growth Cli
Slide 24: Strive25 environmental performance priorities
With Strive25 we put emphasis on improving our environmental performance, while continuing our ongoing commitments Our mission Making life easier for people with intimate healthcare needs Our 2025 priority Our 2025 priority Improving products Reducing emissions and Packaging1 90% of packaging recycl
Slide 25: Yearly incremental investments of up to 2% of revenue
We will continue to support organic growth through yearly incremental investments of up to 2% of revenue in the Strive25 period Key Investment Decision Drivers Key Investment Areas – up to 2% of revenue in incremental OPEX investments Investments made in H1 of Strive25 Continued investments in H2 of
Slide 26: Strive25: M&A plays a bigger role
Strive25: M&A plays a bigger role as we seek to secure long-term growth and value creation options beyond 2025 Opportunity Systematic based screening Large plays Channel expansion Portfolio expansion Early-stage & adjacencies technologies Examples: 2022 US direct-to-consumer TFL Drive DME dealers1 (
Slide 27: Key enablers supporting the Chronic Care commercial model
We have built key enablers to support the commercial model in our Chronic Care businesses Commercial model Key enablers Coloplast® Care Superior, clinically differentiated products Direct to Consumer Consumer Clinical Direct Businesses preference Data and digital tools preference Data & Digital tool
Slide 28: Direct business in Chronic Care drives growth
Direct business in Chronic Care serving consumers drives improved outcomes and is a vital component of our growth Direct presence in top 5 markets and strategic rationale Coloplast Consumer presence (incl. patient support programme, Coloplast® Care) Control and continuity 1 of product supply ~30% MS
Slide 29: Clinical Performance Programme
We have initiated a very ambitious Clinical Performance Programme to tackle the biggest issues users face Continence Care – preventing UTIs remains one of the biggest unmet needs Ostomy Care - Leakage remains the biggest challenge for our users 45 % of users describe UTIs as their greatest challenge
Slide 30: Luja catheter platform with Micro-hole Zone Technology
Luja , our new catheter platform with Micro-hole Zone Technology addresses key UTI risk factors UTI Risk Factor Model1 UTI risk factors addressed by Luja Intermittent General patient catheterisation conditions UTI risk factor: UTI risk factor: Non-hygienic technique Urethral trauma UTI risk factors
Slide 31: Comprehensive clinical program behind Luja
Comprehensive clinical program behind Luja to demonstrate the clinical relevance and difference Pivotal studies 2 multinational pivotal studies2 involving 110+ users demonstrating the impact on the key risk factors of UTIs Pilot studies Multicenter, randomised cross 8 studies comparing Luja vs. over
Slide 32: Data on Heylo is promising
Data on Heylo is promising. First pivotal clinical study showed improvement in quality of life and a 31% reduction in leakage Pre-pilot study on Heylo Pivotal clinical studies on Heylo Product performance & user experience1 First pivotal clinical study on Heylo4, conducted in Germany showed: Using H
Slide 33: Profitability supported by scalability and efficiency gains
Profitability supported by scalability and efficiency gains enabling additional innovation and commercial investments Gross Profit development, % Cost item Development, in % of revenue* FY 22/23 Gross Profit negatively impacted by inflationary headwind on input costs (raw materials, energy, labour).
Slide 34: Global Operations Plans have delivered value since 2008
Global Operations Plans (GOPs) have delivered significant value since 2008, supporting Coloplast’s industry leading profitability 2008 2009 2012 2017 2020 2023-2026 Turn-around GOP1 GOP2/GOP3 GOP4 GOP5 GOP6 Focused Operational Operational Step change Fit for the future Excellence Excellence executio
Slide 35: GOP6 will drive efficiency improvements
GOP6 will support Coloplast’s growth agenda and drive continued efficiency improvements to support EBIT margin ambition Optimize footprint Drive efficiencies in procurement • New manufacturing site of 30,000 m2 in Portugal • Company-wide procurement programme initiated, aimed at driving • Portugal s
Slide 36: Global Business Support and IT landscape
A global Business Support and IT landscape enables Coloplast to scale faster and efficiently and integrate Atos Medical into the Group Global Business Services Global business services handle the majority of all global support % of group processes 100% ~90% 100% 100% IT infrastructure Finance / acco
Slide 37: EBIT margin development drivers
EBIT margin development continues to be a function of growth, scalability, cost discipline and investment activity EBIT margin (%) Illustrative Future drivers of EBIT margin EBIT will be positively impacted by: • Leverage effect on fixed costs e.g. >30% distribution, admin and R&D costs especially d
Slide 38: Continued strong development in free cash flow
Continued strong development in free cash flow during the Strive25 strategy period Taxation Net working capital CAPEX1 Reported tax rate Net working capital, % of revenue CAPEX DKKm Depreciation and amortisation, % of revenue CAPEX, % of revenue 5% 5% 5% 5% 5% 6% 5% 4% ~5% 4% 4% 4% 5% 27% 25% 26% 23
Slide 39: Attractive cash returns to investors
We will continue to provide attractive cash returns despite investments in commercial activities and the Atos Medical and Kerecis acquisitions Coloplast cash distribution to investors Highlights Dividends paid out in the year (DKKm) (1) Share buy-back (DKKm) Pay-out ratio (%) (2) • Coloplast returns
Slide 40: Stable shareholder returns through growth and margin
In sum, we believe Coloplast can continue to deliver stable shareholder returns through ... Organic growth and EBIT margin Highlights 27% • Stable market trends in our Chronic Care business • Innovative product portfolio and new product launches 8% • Strong Coloplast Care retention program and innov
Slide 41: Introduction to Kerecis
Introduction to Kerecis An emerging category leader in the biologics wound care segment
Slide 42: With Kerecis, Coloplast adds a long-term growth business
With Kerecis, Coloplast adds a long-term growth business, uniquely positioned to support long-term value creation Compelling strategic rational Kerecis financial assumptions Performance of Kerecis • Three-year revenue CAGR of ~30% until FY 2025/26 • Attractive gross margin level, accretive to Colopl
Slide 43: Entering the biologics segment
We enter the biologics segment, expanding our footprint in the US and transforming our presence in the global advanced wound care market Addressable advanced wound care market by segment Addressable advanced wound care market Gelling (advanced dressings and biologics) Fibers 2 Advanced 3-5 With Kere
Slide 44: Kerecis fish-skin technology platform
Kerecis is transforming wound healing with its clinically differentiated technology platform based on gently processed fish skin Kerecis key business highlights Started in 2009, with headquarters and manufacturing in Iceland 1 DKK 772m Revenue for FY 2022/23 Proprietary product platform based on int
Slide 45: Fish skin for wound healing in humans
Fish skin – uniquely positioned for wound healing in humans Kerecis fish-skin technology – gently processed, preserving its similarity to human skin Fish Skin for Human Skin* Epidermis Dermis 100 µm 100 µm Advantages of the fish-skin technology: • High resemblance to human skin: similar three-dimens
Slide 46: Clinical evidence with 40+ publications
Comparative RCTs & Second-Degree Burns Difficult Wounds Compelling clinical Prospective Clinical and Excised Full- with Trials Thickness Burns Pain Reduction evidence with 40+ 1. Pending publication: 1. Staubach et al. J Clin Med 1. T. J. Clasen, E. Libich, M. publications showing Complex DFU (n=255
Slide 47: Sustained strong growth momentum at Kerecis
Sustained strong growth momentum through proven commercial model and a purpose-driven organisation Kerecis revenue distribution, H1 2023/24 Sustained strong growth through: By wound type: By care setting: By geography: • Continued strong growth in the US across wound types and care settings US • Acc
Slide 48: Introduction to Atos Medical
Introduction to Atos Medical (Voice and Respiratory Care) The global market leader in laryngectomy Joakim | Provox Life user
Slide 49: Atos Medical market leader in laryngectomy
Atos Medical is the market leader in the attractive chronic laryngectomy market, with strong growth and profitability outlook Key market and business highlights Key financial assumptions Laryngectomy Tracheostomy • Organic growth 8-10% Procedures per year ~50,000 ~1,000,000 Organic growth • Laryngec
Slide 50: Atos improves lives after Total Laryngectomy
Atos improves the lives of patients following Total Laryngectomy procedures A Total Laryngectomy is a non-elective After surgery, a Voice Prosthesis (VP) is inserted by a healthcare professional, surgery performed in the advanced and the patient applies the Heat- and Moisture Exchanger (HME) and adh
Slide 51: Untapped potential in the laryngectomy market
There is significant untapped potential in the laryngectomy market today, which we will seek to eliminate The laryngectomy market, DKKbn Low level of market penetration due to: We will eliminate the ‘white space’ by: Lack of clinical standards in existing 01 markets outside of Northern Europe Settin
Slide 52: Tracheostomy patients have similar needs
Tracheostomy patients have similar needs as laryngectomy patients, as they are both breathing through a neck stoma A Tracheostomy is a surgical The Tracheostomy patient journey starts with a cannula insertion, which can be procedure that creates an opening in reversed at any stage the neck for direc
Slide 53: Appendices
Leading intimate healthcare Leading intimate healthcare Appendices Laura | IC user
Slide 54: The Coloplast share
The Coloplast share (COLO-B.CO) Holders of A shares and family 1 Danish institutions Foreign institutions Coloplast A/S Coloplast share listed on Nasdaq Copenhagen Other shareholders since 1983 Non-registered shareholders 2.0% 6.0% ~210.3 billion DKK (~31 billion USD) market 2.0% cap @ ~934.4 DKK pe
Slide 55: Capital structure
Capital structure Highlights Net interest-bearing debt Overall policy is that excess liquidity is returned to shareholders through a combination of dividends (paid bi-annually) and 2.8x share buy-backs (expected at DKK 500m per year; no buy- 2.4x 2.3x back in FY 23/24). 2.0x Interest bearing debt wi
Slide 56: 9M 2023/24 organic growth of 8%
9M 2023/24 organic growth of 8%, driven by Chronic Care and double- digit growth in Voice & Respiratory Care and Advanced Wound Care 9M 2023/24 revenue by business area 9M 2023/24 revenue by geography Business Reported revenue Organic growth Share of organic Geographic Reported revenue Organic growt
Slide 57: 9M reported revenue grew 10%
9M reported revenue grew 10% with ~4%-points contribution from the Kerecis acquisition and ~2%-points negative impact from currencies 9M 2023/24 Revenue development (mDKK) 9M 2023/24 highlights • Reported revenue increased by DKK 1,803 million or 10% vs. last year. +1,803 • Organic growth was 8% or
Slide 58: Reported EBIT margin of 27% in 9M
Reported EBIT margin of 27%1 in 9M, impacted by currency headwind and ~100 basis points dilution from Kerecis, as expected 9M 2023/24 EBIT margin development before special items (%) 9M 2023/24 highlights • Gross margin was 68%, compared to 67% last year 1.1 -1.8 • Positive impact from: decrease in
Slide 59: Key value ratios
Key value ratios Profitability drivers Free Cash Flow drivers 33.4 36.2 36.8 32.3 32.0 32.5 31.5 31.2 34.6 34.7 32.3 32.1 32.1 30.1 30.7 29.0 28.7 28.2 27.4 26.1 26.3 23.6 23.4 23.7 4.2 4.1 3.9 4.5 4.6 4.8 5.0 5.2 5.0 5.1 4.5 3.5 3.9 3.8 3.9 3.8 3.6 3.5 18/19 19/20 20/21 21/22 22/23 YTD 23/24 18/19
Slide 60: Revenue development by business area
Coloplast revenue development by business area Ostomy Care Interventional Urology Voice & Respiratory Care1 10 8 7 6 6 19 16 Contribution to 7 6%-points 3%-points 5 4 5 6 reported growth 10 14 10% 10% 9,024 10 4 8,620 9 organic growth 7,538 7,841 7,095 3 reported growth -7 8% -7 2,424 2,674 1,835 2,
Slide 61: Revenue development by geography and total
Coloplast revenue development by geography and total Europe Other Developed Markets 15 8 6 2 4 21 19 6 8 12 2 4 5 5 6 6 5 3 6 9 12,916 13,908 11,261 11,037 5,775 6,480 10,820 5,648 4,644 4,785 19/20 20/21 21/22 22/23 YTD 23/24 19/20 20/21 21/22 22/23 YTD 23/24 FY 21/22 and FY 22/23 reported growth r
Slide 62: Segment operating profit
Segment operating profit Segment Operating Profit DKKm (Excludes shared/non-allocated costs) Segment Operating Profit Margin (%) Chronic Care Interventional Urology Voice & Respiratory Care1,2 Adv. Wound Dressings Biologics1,3 Ostomy and Continence Care 36 38 58 58 58 58 58 35 34 34 40 40 36 37 37 3
Slide 63: PPA amortisation impact on EBIT margin
9M 2023/24 Atos Medical and Kerecis PPA amortisation impact on EBIT margin 32% 3% 29% 29% 1% 27% 27% 1% 0% DKK 70 DKK 233 DKK 108 DKK 614 million million million million 9M 2023/24 Special items total1 EBIT margin PPA amortisation2 EBIT margin Amortisation excl. EBITA Depreciation EBITDA EBIT margin
Slide 64: Exchange rate exposure and hedging policy
Exchange rate exposure FY 2023/24 and hedging policy Revenue FX exposure 2023/241) 12 months exposure from 10% initial exchange rate drop1) Other 17% -710 EUR USD -220 34% CNY, JPY, AUD, BRL & ARS 11% -350 GBP -220 HUF 0 13% 130 GBP 25% Revenue (DKKm) EBIT (DKKm) USD Foreign exchange rate guidance f
Slide 65: No significant healthcare reforms expected
No significant healthcare reforms expected in FY 2023/24. The expectation of long-term price pressure of up to 1% p.a. is unchanged Europe Rest of World • Netherlands: Reimbursement pressure on OC and CC • US: CMS reimbursement review of skin substitutes, relating to • France: Reimbursement pressure
Slide 66: Coloplast CARE increases retention and compliance
Coloplast CARE helps us increase retention and improve product compliance We co-develop CARE content with CARE is a personal and “high- Global program with shared local clinicians touch” program infrastructure Advisors available on phone Clinically validated content and call protocol - ERP Website w
Slide 67: Direct-to-Consumer marketing program
With our Direct-to-Consumer marketing program we reach into the community We operate in numerous channels to expose our …and with the reach we get several benefits service and product offering… Introduce innovative products Ensure product accessibility Ensure successful experience 67
Slide 68: Generic model for distribution and reimbursement
The generic model for distribution and reimbursement of our products Prescription & Insurance Product Reimbursement price Prescription & Insurance Payer Distribution Consumer $ Product 68
Slide 69: Interventional Urology revenue balance
Interventional Urology revenue is balanced geographically and across the four business areas Interventional Urology at a Glance ~15% market share in global market of DKK 18-20bn market FY 22/23 growing 4-6% annually 11% Coloplast position, FY 22/23 of Coloplast sales Bladder Health & Endourology Men
Slide 70: Interventional Urology select products
Coloplast Interventional Urology consists of four business areas Men’s Women’s Bladder Health Endourology & Surgery Health Health • Erectile Dysfunction • Stress Urinary Incontinence • Stone Management • Bladder Drainage • Male Incontinence (SUI) • Transurethral • Benign prostatic hyperplasia • Test
Slide 71: Strong presence in Interventional Urology categories
We have a strong presence in our categories in Interventional Urology but there is room to capture market share 1 Men’s Health Women’s Health Endourology Bladder Health & 1 Surgery Inflatable Penile Male Stress urinary Pelvic organ Prosthesis (IPP) incontinence incontinence prolapse Fragmented Compe
Slide 72: Refined product roadmap in Interventional Urology
We are executing a refined product roadmap in Interventional Urology aligned to Strive25; progress is tracking to key milestones Strategy Description Men’s Health Women’s Health Endourology Projects that address regulatory Cadence of stone Strengthen core requirements, close gaps and maintain IPP En
Slide 73: Portfolio expansions with TFL Drive and Intibia
Portfolio expansions in adjacent segments with TFL Drive and Intibia provide strong growth potential for Interventional Urology Target Adjacencies Target Adjacencies AUS ED OAB BPH AUS POP Core SUI Coloplast Endo Consum- Endo TFL Drive Laser ables • Launched in Q4 2021/22 Prostate • State of the art
Slide 74: Intibia option to enter the OAB market
With Intibia , Coloplast obtained an option to enter the attractive OAB market worth around 1bn USD. Launch expected in FY 2025/26 Overactive bladder (OAB) market Why Implantable Tibial Nerve Stimulation (ITNS)? Less invasive ITNS complete in single procedure +80m people globally suffer from OAB sym
Slide 75: Wound & Skin Care 2025 strategic plan
The Wound & Skin Care 2025 strategic plan (Advanced Wound Dressings) Expand in the US Win in Europe Lead in China Outgrow market and deliver competitive profitability Reach full 3DFit Selectively potential invest Selectively expand Drive commercial portfolio excellence 75
Slide 76: In US Ostomy Care we continue to win
In US Ostomy Care we continue to win across the patient pathway We have invested across the care continuum in Strive25 … and are now seeing acute share gains translate into the community US OC patient pathway Bags and plates acute share +7%-pts Acute Post-acute Community 2019 (pre-GPO) H1 23/24 MAT
Slide 77: Awarded access to key GPOs
Coloplast has been awarded access to key GPOs, ensuring a level playing field in ~75% of acute accounts in US Ostomy Care Coloplast has been awarded access to Vizient and Premier, the two largest GPOs in the US Acute members1 Estimated Contract Contract Contract Acute share2 expiry date length type
Slide 78: US Continence Care hydrophilic catheter upgrade
In US Continence Care, we drive the upgrade of the market to hydrophilic catheters and aim to set a new standard of care with Luja We are driving the upgrade to hydrophilic-coated US IC reimbursement categories catheters in the US Hydrophilic catheters as On 16 August 2026, CMS has issued a final co
Slide 79: Sustainability - key priorities and actions
Sustainability - key priorities and actions Improving products Reducing emissions Responsible and packaging operations Why is this a key priority: Why is this a key priority: Why is this a key priority: As a manufacturer of medical products made primarily As a growing company, we are challenged by a
Slide 80: 9M 23/24 progress on sustainability ambitions
9M 23/24 progress on key sustainability ambitions Improving products and packaging Reducing emissions Responsible operations 2025 9M FY 2025 9M FY 2025 9M FY Ambition 23/24 22/23 Ambition 23/24 22/23 Ambition 23/24 22/23 100% 2.5 2.6 90% 2.0 Recyclable 72% Scope 1+2 emissions Lost time injury packag
Slide 81: Ostomy Care
Introducing Key products Ostomy Care • Between 2 and 3 million people live with a stoma globally, ~2/3 in the developed markets • Up to around 300,000 stoma surgeries per year in developed markets and China Disease areas SenSura® Mio in black SenSura® Mio Concave SenSura® Mio Convex SenSura® Mio • C
Slide 82: Ostomy Care Supporting Products
Introducing Key products Ostomy Care Supporting Products Market fundamentals Heylo Brava® Protective Seal Brava® Skin Barrier Brava® Elastic Tape • Market size of DKK ~4bn Digital leakage notification system Designed for leakage Reducing skin problems Elastic so it follows the • Market growth of 6-8
Slide 83: Continence Care
Introducing Key products Continence Care • Intermittent catheters for management of urinary retention and collecting devices for management of urinary incontinence Luja Intermittent catheter with SpeediCath® Flex Set SpeediCath® Navi SpeediCath® Flex • Around 6 million people live with urinary reten
Slide 84: Bowel Care
Introducing Key products Bowel Care Market fundamentals • Market size for transanal irrigation of DKK ~1bn • High-single digit market growth Peristeen® Light Peristeen® Plus Peristeen® Transanal Irrigation Transanal Irrigation Transanal Irrigation Disease areas Launched in 2024 Launched in 2021 Laun
Slide 85: Laryngectomy
Introducing Key products - Laryngectomy Voice & Respiratory Care Provox® Life Laryngectomy Heat and Moisture Exchangers (HMEs) Home Go Night Protect Energy Free hands Disease areas • People that have undergone a total laryngectomy, a typical treatment for advanced Provox® Life laryngeal and hypophar
Slide 86: Tracheostomy
Introducing Voice & Respiratory Care Tracheostomy Disease areas Key products - Tracheostomy • Performed when the airways are restricted, e.g., during an emergency when the airways are blocked, or when a Portfolio expansion disease or other problem makes normal breathing impossible • Strengthened the
Slide 87: Interventional Urology
Introducing Key products Interventional Urology • Men’s Health: men with erectile dysfunction. ~25% of men aged 40-70 years old experience moderate to severe erectile dysfunction. • Women’s Health: women with pelvic organ prolapse and stress urinary incontinence. ~50% of women 50- 79 years old repor
Slide 88: Advanced Wound Dressings
Key products Introducing Advanced Wound Dressings Disease areas Biatain® Silicone Fit Biatain® Silicone Non-Border Biatain® Fiber Biatain® Contact Silicone foam dressing for Silicone foam dressing without a Reinforced gelling fiber. Silicone contact layer. Chronic wounds pressure injury prevention b
Slide 89: Skin Care
Introducing Key products Skin Care Disease areas • Moisture associated skin damage Sween® EasiCleanse® Bath • Incontinence Broad line of skin care products Disposable bathing wipes • Skin folds & obesity Designed to increase consistency of care Improves patient experience • Prevention of skin impair
Slide 90: US Skin Care
At a glance US Skin Care US Skin Care market Market Market drivers drivers andand limiters limiters + +AgingAging and obese population and obese population US market size estimated + +CMSCMSValueValue BasedBased Purchasing Purchasing at DKK ~5bn with 2-4% growth + +Increased focusfocus Increased on
Slide 91: Coloplast organisation structure
The Coloplast organisation is divided into Chronic Care and Strategic Business Units, running on shared global business support functions Coloplast Group Chronic Care Strategic Business Unit Advanced Interventional Voice & Ostomy Care Continence Care Biologics (Kerecis) Wound Dressings Urology Respi
Slide 92: The Coloplast Executive Leadership Team
The Coloplast Executive Leadership Team Kristian Villumsen President, CEO (Born 1970) With Coloplast since 2008 Nicolai Buhl Andersen Anders Lonning-Skovgaard Paul Marcun Dorthe Rønnau Allan Rasmussen EVP, Innovation EVP, CFO EVP, Growth SVP, People & Culture EVP, Operations (Born 1969) (Born 1972)
Slide 93: Income statement
Income statement DKKm Q3 2022/23 Q3 2023/24 Change 9M 2022/23 9M 2023/24 Change Revenue 6,108 6,885 13% 18,274 20,077 10% Gross profit 4,023 4,648 16% 12,196 13,629 12% SG&A costs -2,128 -2,551 20% -6,449 -7,492 16% R&D costs -216 -240 11% -641 -694 8% Other operating income/expenses 7 13 86% 25 40
Slide 94: Balance sheet
Balance sheet DKKm 30 Jun 2023 30 Jun 2024 Change Balance, total 37,577 48,580 29% Assets Non-current assets 27,904 37,940 36% Current assets 9,673 10,640 10% of which: Inventories 3,557 3,676 3% Trade receivables 4,072 4,835 19% Marketable securities, cash, and cash equivalents 855 887 4% Other rec
Slide 95: Cash flow
Cash flow DKKm 9M 2022/23 9M 2023/24 Change EBIT 5,126 5,413 6% Amortisation 245 341 39% Depreciation 547 614 12% Adjustment for other non-cash operating items -166 -41 -75% Change in working capital -1,314 -1,256 -4% Net interest payments -582 -580 0% Paid tax -1,511 -3,773 150% Cash flow from oper
Slide 96: Manufacturing setup
Manufacturing setup Production by country (Volume)¹ 7% 0% 3% Isafjordur Hungary 6% 0% China Hörby 10% US/France Mørdrup Tatabánya Denmark Minneapolis Nieder-Olm Nyirbátor Mankato Sarlat Zhuhai Costa Rica 75% Atos (SE/DE) Kerecis (Iceland) Costa Rica COGS by cost type² 13% 8% Salary - Direct Salary -
Slide 97: Production sites
Production sites Hungary China Tatabánya Zhuhai • Continence care products • Ostomy care products • Ostomy care products • Adhesives • Machine building • Continence care products • Number of employees in production: ~800 • Interventional Urology products • Number of employees in production: ~1,650 C
Slide 98: Production sites
Production sites France Sweden Sarlat Hörby • Disposable surgical urology products • Research & Development centre and • Number of employees in production: ~250 manufacturing of laryngectomy products • Number of employees in production: ~120 US Germany Minneapolis Nieder-Olm • Interventional Urology
Slide 99: Coloplast Sponsored Level 1 ADR programme
Coloplast Sponsored Level 1 ADR programme Coloplast Sponsored ADR Programme Benefits of a Coloplast ADR programme to US Investors: • Coloplast has established a sponsored ADR programme in the US, as a Symbol CLPBY service to US investors by offering an alternative way to trade Coloplast shares, whil
Slide 100: Contact Investor Relations
Contact Investor Relations Holtedam 1 DK-3050 Humlebæk Denmark Aleksandra Dimovska Kristine Husted Munk Vice President, Investor Relations Senior Manager, Investor Relations Tel. direct: +45 4911 2458 Tel. direct: +45 4911 3266 Office: +45 4911 1800 Office: +45 4911 1800 dkadim@coloplast.com dkkhu@c
Slide 101: Mission, values and vision
Mission Making life easier for people with intimate healthcare needs Values Closeness… to better understand Passion… to make a difference Respect and responsibility… to guide us Vision Setting the global standard for listening and responding